Treatment strategies in psoriatic arthritis

被引:0
|
作者
Koehm, Michaela [1 ,2 ,3 ]
Burkhardt, Harald [1 ,2 ,3 ]
Behrens, Frank [1 ,2 ,3 ]
机构
[1] Goethe Univ Frankfurt Main, Abt Rheumatol, Theodor Stern Kai 7, D-60596 Frankfurt, Germany
[2] Fraunhofer IME, Inst Translat Med & Pharmakol TMP, Frankfurt, Germany
[3] Fraunhofer Exzellenzcluster Immunmediierte Erkran, Frankfurt, Germany
关键词
psoriatic arthritis; treatment recommendations; GRAPPA; personalized treatment strategies; CONTROLLED-TRIAL; RECOMMENDATIONS; SECUKINUMAB; MULTICENTER; MANAGEMENT; THERAPIES; UPDATE;
D O I
10.1055/a-1676-9290
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriatic arthritis is a heterogeneous immune-mediated disease that usually involves skin and joints but can also affect entheses and extraarticular structures in the disease course. In addition, associated diseases must be considered when choosing the appropriate therapeutic strategy. Different recommendations for treatment of psoriatic arthritis are available for clinical use. The recommendations of the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) are the two internationally accepted guidelines frequently used to assist therapeutic decisions in clinical practice. New targeted treatment options developed based on a better knowledge of critical pathogenic pathways, will enlarge our armamentarium for optimized pharmacotherapy of psoriatic arthritis and improve personalized patient care.
引用
收藏
页码:544 / 551
页数:8
相关论文
共 50 条
  • [31] Adalimumab for the treatment of psoriatic arthritis
    Poddubnyy, Denis A.
    Rudwaleit, Martin
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (06) : 671 - 681
  • [32] Diagnosis and treatment of psoriatic arthritis
    Mease, P
    Goffe, BS
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (01) : 1 - 19
  • [33] Biosimilars for the treatment of psoriatic arthritis
    Cantini, Fabrizio
    Benucci, Maurizio
    Gobbi, Francesca Li
    Franchi, Giulia
    Niccoli, Laura
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (11) : 1195 - 1203
  • [34] Ustekinumab for the treatment of psoriatic arthritis
    Chandler, David John
    Bewley, Anthony
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (02) : 111 - 121
  • [35] Treatment recommendations for psoriatic arthritis
    Boehncke, W. -H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2009, 68 (10): : 842 - 844
  • [36] Apremilast for the treatment of psoriatic arthritis
    Varada, Sowmya
    Tintle, Suzanne J.
    Gottlieb, Alice B.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (03) : 239 - 250
  • [37] Bimekizumab for the treatment of psoriatic arthritis
    Tanaka, Yoshiya
    Shaw, Stevan
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (02) : 155 - 168
  • [38] Leflunomide in the treatment of psoriatic arthritis
    Lopez-Medina, Clementina
    Schiotis, Ruxandra
    Collantes-Estevez, Eduardo
    LANCET RHEUMATOLOGY, 2022, 4 (04): : E230 - E231
  • [39] TREATMENT OF PSORIATIC-ARTHRITIS
    GOUPILLE, P
    VALAT, JP
    ANNALES DE MEDECINE INTERNE, 1994, 145 (03): : 205 - 214
  • [40] ADVANCES IN THE TREATMENT OF PSORIATIC ARTHRITIS
    Helliwell, Philip
    RHEUMATOLOGY, 2012, 51 : 16 - 16